ReviewNature reviews. Cancer2020
How the ageing microenvironment influences tumour progression.
Review in Nature reviews. Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 556 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
556 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Construction and validation of a prediction system for postherpetic neuralgia: based on meta-analysis.Scientific reports · 2026Pooled it
- Associations of exposure to PMBMC public health · 2025Pooled it
- A systematic review and meta-analysis of incidence trends and risk factors for metachronous gastric lesions following endoscopic resection.Annals of medicine · 2025Pooled it
- Multidisciplinary intervention in frail elderly patients with cardiovascular diseases: a multicentre, single-blinded, randomised controlled trial.Nature communications · 2026Trial
- Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial.Nature aging · 2025Trial
- Vascular aging as a driver of organ dysfunction and systemic aging.Nature cardiovascular research · 2026Review
- Clinical metastatic cancer from initiation to colonization: emerging challenges and breakthroughs.Oncogene · 2026Review
- Why Some People Live Past 100: The Role of the Immune System in Centenarians, Semi-Supercentenarians and Supercentenarians.International journal of molecular sciences · 2026Review
- The long-lived immune system of centenarians.Nature reviews. Immunology · 2026Review
- Colorectal Cancer Liver Metastasis-Associated Ferroptosis-Related Genes Modulate Lipid Peroxidation in Colorectal Cancer Cells.Molecular carcinogenesis · 2026Article
- Loss of endothelial cell FAK represses cisplatin-induced vascular senescence in distal niches to reduce lung metastatic burden.Research square · 2026Article
- Review
- Immune surveillance and immune evasion of senescent cells.Nature reviews. Immunology · 2026Review
- Biological aging and generational shifts in early-onset cancer risk.Nature medicine · 2026Article
- Natural products targeting cytokine-regulated SASP inflammation networks in Ovarian cancer: Implications on immune escape and molecular resistance.Inflammopharmacology · 2026Review
- Host-Pathogen Interaction as a Driver of Cellular Senescence: Microbial Triggers and Host Response.International journal of molecular sciences · 2026Review
- Bacteria mediated tumor therapy recent advances challenges and future perspectives.Discover oncology · 2026Review
- Ovarian cancer-derived ADAMTS2 promotes the omental pre-metastatic niche formation through remodeling collagen I.Biology direct · 2026Article
- Development of a Combined Risk Factors Prediction Model for Esophageal Squamous Cell Carcinoma: A Secondary Analysis of the Linxian Nutrition Intervention Trial Cohort.Research square · 2026Article
- Major Postoperative Complications and Survival After Lung Cancer Resection in Patients Aged ≥80 Years: Risk Factor Analysis.Current oncology (Toronto, Ont.) · 2026Article
496 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Most cancers arise in individuals over the age of 60. As the world population is living longer and reaching older ages, cancer is becoming a substantial public health problem. It is estimated that, by 2050, more than 20% of the world's population will be over the age of 60 - the economic, healthcare and financial burdens this may place on society are far from trivial. In this Review, we address the role of the ageing microenvironment in the promotion of tumour progression. Specifically, we discuss the cellular and molecular changes in non-cancerous cells during ageing, and how these may contribute towards a tumour permissive microenvironment; these changes encompass biophysical alterations in the extracellular matrix, changes in secreted factors and changes in the immune system. We also discuss the contribution of these changes to responses to cancer therapy as ageing predicts outcomes of therapy, including survival. Yet, in preclinical studies, the contribution of the aged microenvironment to therapy response is largely ignored, with most studies designed in 8-week-old mice rather than older mice that reflect an age appropriate to the disease being modelled. This may explain, in part, the failure of many successful preclinical therapies upon their translation to the clinic. Overall, the intention of this Review is to provide an overview of the interplay that occurs between ageing cell types in the microenvironment and cancer cells and how this is likely to impact tumour metastasis and therapy response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.